US2006199793A1PendingUtilityA1
Sterol absorption inhibitor compounds
Est. expiryJan 26, 2021(expired)· nominal 20-yr term from priority
A61P 9/04A61P 3/06A61P 43/00A61P 3/10A61P 9/00A61P 9/10A61P 3/04A61K 31/216A61P 3/00A61K 45/06A61K 31/397A61K 31/165A61K 31/055A61K 31/03
50
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.
Claims
exact text as granted — not AI-modified1 - 101 . (canceled)
102 . A pharmaceutical composition consisting of:
Weight
percent of
Ingredient
ingredient
Compound of Formula (II)
10
Lactose monohydrate
55
Microcrystalline cellulose
20
Povidone
4
Croscarmellose sodium
8
Sodium lauryl sulfate
2
Magnesium stearate
1
Total
100
wherein the compound represented by Formula (II) below is:
and wherein the pharmaceutical composition is effective for treating a vascular condition in a mammal.
103 . A pharmaceutical composition consisting of:
Weight
percent of
Ingredient
ingredient
Compound of Formula (II)
10
Lactose monohydrate
55
Microcrystalline cellulose
20
Povidone
4
Croscarmellose sodium
8
Sodium lauryl sulfate
2
Magnesium stearate
1
Total
100
wherein the compound represented by Formula (II) below is:
and wherein the pharmaceutical composition is effective for treating diabetes in a mammal.
104 . A pharmaceutical composition consisting of:
Weight
percent of
Ingredient
ingredient
Compound of Formula (II)
10
Lactose monohydrate
55
Microcrystalline cellulose
20
Povidone
4
Croscarmellose sodium
8
Sodium lauryl sulfate
2
Magnesium stearate
1
Total
100
wherein the compound represented by Formula (II) below is:
and wherein the pharmaceutical composition is effective for treating obesity in a mammal.
105 . A pharmaceutical composition consisting of:
Weight
percent of
Ingredient
ingredient
Compound of Formula (II)
10
Lactose monohydrate
55
Microcrystalline cellulose
20
Povidone
4
Croscarmellose sodium
8
Sodium lauryl sulfate
2
Magnesium stearate
1
Total
100
wherein the compound represented by Formula (II) below is:
and wherein the pharmaceutical composition is effective for lowering a plasma sterol concentration of a mammal.
106 . A pharmaceutical composition consisting essentially of:
milligrams
of
Ingredient
ingredient
Compound of Formula (II)
10
Lactose monohydrate
55
Microcrystalline cellulose
20
Povidone
4
Croscarmellose sodium
8
Sodium lauryl sulfate
2
Magnesium stearate
1
Total
100
wherein the compound represented by Formula (II) below is:
and wherein the pharmaceutical composition is effective for treating a vascular condition in a mammal.
107 . A pharmaceutical composition consisting essentially of:
milligrams
of
Ingredient
ingredient
Compound of Formula (II)
10
Lactose monohydrate
55
Microcrystalline cellulose
20
Povidone
4
Croscarmellose sodium
8
Sodium lauryl sulfate
2
Magnesium stearate
1
Total
100
wherein the compound represented by Formula (II) below is:
and wherein the pharmaceutical composition is effective for treating diabetes in a mammal.
108 . A pharmaceutical composition consisting essentially of:
milligrams
of
Ingredient
ingredient
Compound of Formula (II)
10
Lactose monohydrate
55
Microcrystalline cellulose
20
Povidone
4
Croscarmellose sodium
8
Sodium lauryl sulfate
2
Magnesium stearate
1
Total
100
wherein the compound represented by Formula (II) below is:
and wherein the pharmaceutical composition is effective for treating obesity in a mammal.
109 . A pharmaceutical composition consisting essentially of:
milligrams
of
Ingredient
ingredient
Compound of Formula (II)
10
Lactose monohydrate
55
Microcrystalline cellulose
20
Povidone
4
Croscarmellose sodium
8
Sodium lauryl sulfate
2
Magnesium stearate
1
Total
100
wherein the compound represented by Formula (II) below is:
and wherein the pharmaceutical composition is effective for lowering a plasma sterol concentration of a mammal.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.